Moderna's (NASDAQ: MRNA ) stock has continued to fall in 2025, despite a new vaccine approval and additional clinical readouts ahead. In January, I rated MRNA a sell, expecting the company would continue burning cash with little to show for itScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclo ...